The hunting of the sarcoma
|
|
- Vivian Palmer
- 6 years ago
- Views:
Transcription
1 The hunting of the sarcoma Update of Recent Advances in Soft Tissue Sarcoma Treatment Lin Mei, MD Hematology-Oncology Fellow
2 Educational goal Anecdote of sarcoma (10 quiz) Review of pathology Neoadjuvant and adjuvant chemotherapy for early stage STS Traditional chemotherapy for advanced/metastatic STS Treatment for specific subtypes of sarcoma First-line treatment and second- or third-line chemotherapy New advances, e.g. immunotherapy
3 1.7-million-year old bone Dr. Aufberdeide found the first evidence of cancer inside of mummy at Chiribaya site, Peru Osteosarcoma
4 Joseph Lister and cancer In 1869, Lister removed a breast tumor from his sister with antiseptic approach. He performed amputation of a 13-year-old boy with sarcoma of thigh
5 Radium and cancer In late 1920s, it was found radium exposed workers easily developed sarcoma. Emil Grubbe assembled the first x-ray machine in Chicago in 1896 to treat a woman with breast cancer.
6 Father of cancer immunology William Coley In 1893, Dr. Coley found a sarcoma case (Fred Stein), whose tumor disappeared following high fever from Strep Pyogenes at MSKCC, which start the era of cancer immunology. Coley vaccine is from dead bacteria However, his idea majority disagreed from another famous person.
7 Small blue cell Cancer man: James Ewing In 1910, Ewing established a collaboration with a hospital called Memorial Hospital, which nowadays named MSKCC In 1919, he published a book: Neoplastic disease: a textbook on tumors, which established numerous oncological terms In 1920, he named a malignant osteoma: Ewing sarcoma
8 Starving cancer Otto Warburg and Paul Ehrlich studied starving sarcoma cells of metabolites, or tricking them into death by decoy molecules. Warburg effect
9 Cancer can be contagious? Peyton Rous: Nobel Prize in 1966 (40 years after his discovery) Cancer could be transmitted by a virus (now known as Rous Sarcoma Virus) and caused sarcoma of chicken. His son-in-law: Alan Hodgkin ( ), Nobel prize in Hodgkin s lymphoma? Thomas Hodgkin ( ) was his ancestor.
10 Oncogene Harold Varmus and Michael Bishop won the Nobel Prize in 1989 due to the identification of c-src gene that gave rise to the v-src oncogene of Rous Sarcoma Virus (RSV), which was isolated by Peyton Rous in 1910.
11 Epidemiology In 2016, 1.6 million new cancer cases in US Only 1% of case present with sarcoma 12,310 cases of soft tissue sarcoma and 3,300 cases of bone/joint sarcoma Death rate increased from 2003 to 2012 Five-year survival is 80%. (In 1970s is around 70s). Siegel R, et al. CA Cancer J Clin, 2016; 66: 7-30.
12 Pathology Adipose tissue: liposarcoma Peripheral nervous tissue: nerve sheath tumor Smooth muscle: leiomyosarcoma Fibrous tissue: desmoid fibromatosis, fibrosarcoma, etc. Blood vessel: angiosarcomam etc. Skeletal muscle: rhabdomyosarcoma Unknown origin: synovial sarcoma, UPS, epithelioid sarcoma, extraskeletal- osteosarcoma, chondrosarcoma, Ewing sarcoma
13 Pathology
14 Heterogeneity
15 History: doxorubicin Gianni Bonadonna ( ): breast cancer oncologist. He reported Adriamycin showed anti-tumor activity against a variety of solid tumor in 1970 Similar result was replicated at NCI by Dr. Robert Benjamin in Benjamin R. Tumori 2017; 103: 213.
16 Adjuvant chemotherapy OS benefit from doxorubin-based chemo is only 7% (Sarcoma Meta-analysis Collaboration 1997) Ifosfamide-containing regimen improved both PFS (48 vs. 16 mos)and OS (75 vs. 46 mos) [Frustaci S, et al. JCO, 2001; 19: 1239] Three cycles anthracycline-based regimen is non-inferior to 5 cycles. [Gronchi A et al. Ann Oncol 2016; 27: 2283.] Consider it in tumor size>5cm, highgrade histology and deep soft tissue involvement.
17 Adjuvant chemotherapy EORTC trial evaluate doxorubicin and ifosfamide for resected STS 351 pts were enrolled. Grade II-III STS, ECOG<2. Adjuvant chemotherapy(doxorubicin+ifosfamide q3w for 5 cycles) vs. observation OS: chemo (11.2 yr) vs. control (12.4 yr), no significant difference RFS: chemo (7.55 yr) vs. control (6.50 yr)no significant difference 5 yr OS rate: chemo (66.5%) vs. control (67.8%) Subgroup analysis showed limb STS, high grade and large tumor might be beneficial. Woll PJ et al. Lancet Oncol. 2012; 13: 1045.
18 Neoadjuvant treatment Gronchi A et al. reported equal efficacy of neo- and adjuvant chemotherapy. [Ann Oncol. 2016; 27: 2283.] What we are using at VCU is adopted from Stubbe F et al, using AIM plus concurrent radiotherapy with 100% local control rate in 1 year and 89.9% in 3 year. [Cancer Radiother, 2016; 20:6]
19 ISG-STS 1001 Trial Phase 3 histotype-tailored neoadjuvant chemotherapy vs. standard chemotherapy in high-risk STS Epirubicin+Ifos (standard), Trabectedin (myxoid liposarcoma), Gem+dacarbazine (leiomyosarcoma), synovial (high dose Ifos), Etoposide+Ifos (PNST), Gem+docetaxel (UPS). Postoperatively radiation DFS: 46 mos (62%) in standard vs mos (38%) in tailored group OS: at 46 months, 89% in standard vs.64% in tailored groups (P=0.03) Neutropenia: 86% in standard and 26% in tailored groups Conclusion: No benefit of histotype-tailored chemotherapy regimen over standard care. Lancet Oncol 2017; 18:
20 ISG-STS 1001 Trial
21 Conclusion Adjuvant chemotherapy for early stage STS is controversial. Using anthracycline, the absolute benefit of OS is about 4% For extremity sarcoma, the benefit is about 7% Combined anthracycline+ifosfamide, the OS reduction is about 10% Visceral or abdominal sites STS seems not benefit from adjuvant treatment. Grade 1 or 2 STS is not benefit from adjuvant treatment. Neoadjuvant treatment Equal efficacy of neoadjuvant vs. adjuvant chemotherapy Anthracycline is the mainstay treatment. No benefit of histotype-tailored chemotherapy regimen Whether it helps local control still need further evidence.
22 Metastatic and advanced STS: First-line treatment
23 Doxorubicin Historically, combination with dacarbazine and ifosfamide improves responses but not PFS or OS. No RTC trials were done. Phase 3 trial (EORTC 62012), 455 pts from Europe: Dox+Ifos (25mg/m 2 /d D1-D3+2.5g/m 2 /d D1-D4) vs Dox alone (75mg/m 2 on D1) every 3 weeks (6 cycles) Dox+Ifos has higher response rate vs. Dox alone (26% vs. 14%) and longer PFS (7.4 vs. 4.6 mos). OS was not significantly different (14.3 vs months). 1 year survival rate: 60% vs. 51%. Authors called negative result. However Judson I et al. Lancet Oncol 2014; 15: 415
24 Doxorubicin
25 Palifosfamide and Evofosfamide PICASSO III trial: evaluate doxorubicin+palifosfamide vs. doxorubicin alone in advanced/metastatic STS (first line, phase 3) Palifosfamide: metabolite of ifos, not require prodrug activation, less toxicity 447 pts were assigned PFS: doxo (6.0 mos) vs. palifos+doxo (5.2 months) Median OS: doxo (16.9 mos) vs. palifos+doxo (15.9 mos) Higher grade 3-4 AE: 63.6% vs. 50.9% Neutropenic fever: 21.4% vs. 12.6% SARC 021 trial: evaluate doxorubicin+evofosfamide vs. doxorubicin alone in advanced/metastatic STS (first line, phase 3) Evofosfamide: hypoxia-activated prodrug 640 pts were assigned Median OS: doxo (19.0 mos) vs. Evo+doxo (18.4 mos) Ryan C et al. JCO. 2016; 34: 3898 Tap W et al. Lancet Oncol. 2017; 18: 1089
26 Gemticabine+docetaxel First reported from MSKCC in 2002 for leiomyosarcoma (LMS). First line or progressed after doxorubicin-based therapy The phase II trial extended to metastatic STS (sarcoma alliance study 002), including 122 pts Gemcitabine vs. Gemcitabine+docetaxel ORR was 8% (Gem) vs. 16% (Gem+docetaxel) PFS: 3.0 months (Gem) vs. 6.2 months (Gem+docetaxel) Median OS: 11.5 months (Gem) vs months (Gem+docetaxel) Toxicity: no significant higher rate in combination therapy than single agent Grade 3-4: Neutropenia (16 vs 28%), anemia (7 vs. 13%), Neutropenic fever (5 vs. 7%) Then the question is doxorubicin vs. Gem+docetaxel, which one is better? Hensley ML et al. JCO, 2002; 20: 2824 Maki RG et al. JCO, 2007; 25: 2755
27 Sarcoma alliance study 002 ECOG PS=0 ECOG PS>0 ECOG PS=0 ECOG PS>0
28 GeDDis Trial Phase III trial compared gem+docetaxel vs. doxorubicin as first-line treatment for advanced/metastatic STS. Dox 75mg/m 2 q3w; vs. Gem (675mg/m 2, D1, D8)+docetaxel (75mg/m 2 on D8), q3w 257 pts were enrolled (129 to dox and 128 to Gem+docetaxel), f/u 22 mos 6 months PFS: no difference (46.3% vs. 46.4%) Median PFS: no difference (23.3 weeks vs weeks) Toxicity Neutropenia (25% vs. 20%); fatigue (6% vs. 14%) Neutropenic fever (20% vs. 12%); mucositis (14% vs. 2%) Questions Lower than standard gemcitabine dose (900mg/m 2 ), capped at 6 cycles Many pts cross over to doxorubicin group, but less cross over to Gemcitabine group Seddon B, et al. Lancet Oncol. 2017; 18: 1397.
29 GeDDis Trial
30 Olaratumab Olaratumab: monoclonal antibody against PDGFRα Phase Ib/II open-label trial 133 pts were enrolled, advanced/metastatic STS not treated with anthracycline Doxorubicin (75mg/m 2 )+olaratumab (15mg/kg, D1, D8) vs. doxorubicin (D1) q3w Median PFS: 6.6 months (combination) vs. 4.1 months (single agent) Median OS: 26.5 months (combination) vs moths (single agent) p= ORR: 18.2% (combination) vs. 11.9% (single agent) Toxicity: more neutropenia, mucositis, N/V/D. Similar rate of neutropenic fever Oct 2016, FDA approved olaratumab as first-line treatment in combination with doxorubicin. NCCN category 2A recommendation Tap W et al. Lancet. 2016; 388: 488
31 Olaratumab
32 Conclusion Doxorubicin remains the mainstay first-line treatment. Although EORTC trial is negative, however, adding ifosfamide shows increased ORR, PFS, and potential OS. It can be considered for large tumor burden, symptomatic and fit pt, or improve likelihood of tumor control from surgery or radiation. Gemcitabine+docetaxel has comparable efficacy with doxorubicin, though it is lack of clear evidence. It is better tolerate and can be use in prolonged duration. Olaratumab is a very promising agent which shows improved OS in combination with doxorubicin. However, we are still awaiting phase 3 result.
33 Specific subtypes of STS: 2nd-line treatment or more
34 Trabectedin and L-type STS Trabectedin: bind to DNA affect DNA synthesis Trabectedin plus doxorubicin didn t show superiority over doxorubicin alone as first-line treatment for STS Phase III trial evaluate efficacy and safety of trabectedin for metastatic liposarcoma(lps) or leiomyosarcoma (LMS) 518 pts were enrolled, compare trabectedin (n=345) vs. darcarbazine (n=173) After prior therapy with anthracycline and at least one additional regimen 45% reduction in the risk of disease progression or death Median PFS (trabectedin vs. dacarbazine): 4.2 vs. 1.5 months Median OS: 12.4 vs months Benefit all preplanned subgroup Toxicity: myelosuppression and transaminases FDA approved trabectedin for L-type STS after anthracycline treatment. Martin-Broto J et al. JCO; 2016: 34: 2294 Demetri GD et al. JCO; 2016: 34: 786
35 Trabectedin and L-type STS
36 Eribulin Eribulin: antimitotic agent inhibits microtubule. Phase 3 trail evaluate Eribulin vs. Dacarbazine in advanced LMS and LPS received at least two previous treatment. Eribulin 1.4mg/m 2 D1, D8/q3w (n=228), dacarbazine q3w (n=224) OS: Eribulin (13.5 months) vs. dacarbazine (11.5 months) Toxicity grade 3 or higher: Eribulin (67%) vs. dacarbazine (56%) More favor LPS renders FDA approval for LPS on Jan 2016 Subgroup analysis from the same trial reported in Oct 2017 In LPS group, OS: Eribulin (15.6 months) vs. dacarbazine (8.4 months) PFS: Eribulin (2.9 months) vs. dacarbazine (1.7 months) Toxicity: similar Not showing efficacy in other types of STS Eribulin approved for LPS after anthracycline treatment. Schoffski P et al. Lancet. 2016; 387:1629 Demetri GD et al. JCO. 2017; 35: 3433 Schoffski P et al. Lancet Oncol. 2011; 12: 1045
37 Eribulin
38 Pazopanib Pazopanib: multi-kinase inhibitor PALETTE trial: phase 3 trial, evaluate pazopanib for STS progressed from standard chemotherapy. 369 pts were assiagned: pazopanib (800mg qd) (n=246) vs. placebo (n=123) Median PFS: pazopanib (4.6 months) vs. placebo (1.6 months) OS: pazopanib (12.5 months) vs. placebo (10.7 months) LPS or GIST were not included FDA approved for non-adipocytic STS as 2 nd -line treatment on Apr 2012 Van der Graff WT, et al. Lancet. 2012; 379: 1879.
39 Pazopanib
40 Other Ifosfamide: active for synovial sarcoma and myxoid LPS, but less active for LMS Dacarbazine: modest activity against LMS Paclitaxel: active against angiosarcoma Sorafenib: against angiosarcoma and desmoid tumor Sunitinib: against alveolar soft part sarcoma Everolimus: approved for angiomyolipoma associated with tuberous sclerosis
41 New advanced in STS: immunotherapy and more
42 SARC028 trial Phase II trial, evaluate pembrolizumab for safety and activity in advanced STS or bone sarcoma Enrolled 86 pts 18% had ORR (40% for UPS, 20% for LPS, and 10% for synovial) None of the LMS had response 5% of bone sarcoma had ORR (5% of osteosarcoma and 20% chondrosarcoma) None of the Ewing sarcoma had response Toxicity: Hematological and prolonged PTT. 10% had severe irae Pembrolizumab showed more efficacy in UPS and LPS Pre-treatment PD-L1 and MSI status are investigated in the ongoing SARC028 and PembroSARC trials. Tawbi HA, et al. Lancet. 2017, Oct 4 th, epub
43 SARC028 trial
44 Immunotherapy A single center phase 2 study, Nivolumab single agent failed to show any response to previous treated advanced ulms, regardless of PD-L1 expression. A phase 2 study to evaluate pembrolizumab+ctx. 57 pts were included. Four cohorts: LMS, UPS, GIST and others Nonprogression rate: LMS (0%), UPS (0%), GIST (11%) and others (14%). Strong IDO1 expression on macrophage was observed in majority of STS. Combined IDO inhibition might need to be considered in the future Alliance A091401: phase 2 study of nivolumab +/- ipilimumab for metastatic sarcoma (ASCO 2017) 85 pts were enrolled. LMS (36%), LPS (4%), UPS (10%), Synovial (6%), bone (5%) and Ewing (5%), others (34%). Refractory to at least first-line treatment and >50% pts received three or more lines of treatment RR: N(2%) vs. N+I(6%); PFS: N(2.6) vs. N+I (4.5); OS: N(8.7) vs. N+I (11.2) 6 months PFS: N (16%) vs. N+I (36%) Ben-Ami E et al. Cancer. 2017; 123: 3285 Toulmonde M et al. JAMA Oncol. Jun epub
45 Aldoxorubicin Aldoxorubicin (INNO-206): prodrug of doxorubicin, bind to albumin, released in the acidic tumor environment. Phase 2b trial: evaluate first-line aldoxorubicin vs. doxorubicin in advanced STS. 140 pts were enrolled. Aldoxorubicin (350mg/m 2, equal to dox 260mg/m 2 ) or doxorubicin 75mg/m 2, q3w, for 6 cycles. Median PFS: Aldox (5.6 months) vs. dox (2.7 months) P=0.02 Median OS: Aldox (15.8 months) vs. dox (14.3 months) P=0.21 ORR: Aldox (25%) vs. Dox (0%) Toxicity: Gr 3 neutropenia: Aldox (29%) vs. Dox (12%), similar of febrile neutropenia, no EF reduced <50% in Aldox Chawla SP et al. JAMA Oncol. 2015; 1: 1272.
46 Conclusion 2 nd -line treatment Trabectedin for L-typed sarcoma progressed after anthracycline Eribulin for liposarcoma progressed after anthracycline Pazopanib for non-adipocytic (LPS) sarcoma Current immunotherapy result for STS is disappointing. Further study may need to investigate better biomarker and tumor environment (e.g. IDO).
47 Thank you!
I sarcomi dei tessuti molli
Novità e sequenze terapeutiche nelle neoplasie ginecologiche, melanoma e tumori rari: I sarcomi dei tessuti molli Giacomo G. Baldi Oncologia Medica Sandro Pitigliani Nuovo Ospedale S.Stefano Azienda USL
More informationLa chemioterapia neoadiuvante nei sarcomi: novità e attuali indicazioni Lorenzo D Ambrosio, MD PhD Divisione di Oncologia Medica Istituto di Candiolo
La chemioterapia neoadiuvante nei sarcomi: novità e attuali indicazioni Lorenzo D Ambrosio, MD PhD Divisione di Oncologia Medica Istituto di Candiolo Fondazione del Piemonte per l Oncologia. IRCCS 12 CONGRESSO
More informationManaging adult soft tissue sarcomas and gastrointestinal stromal tumours
Managing adult soft tissue sarcomas and gastrointestinal stromal tumours Sarcomas and gastrointestinal stromal tumours include a wide variety of biologically diverse cancers, many of them very rare. Paolo
More informationTrabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract
Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,
More informationIan Judson and Winette T. van der Graaf
SARCOMA Olaratumab really a breakthrough for soft-tissue sarcomas? Ian Judson and Winette T. van der Graaf In a recent study, the addition of olaratumab to doxorubicin chemotherapy for patients with soft-tissue
More informationArticle: Young, R.J. and Woll, P.J. (2016) Eribulin in soft-tissue sarcoma. Lancet, 387 (10028). pp ISSN
This is a repository copy of Eribulin in soft-tissue sarcoma.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/95897/ Version: Accepted Version Article: Young, R.J. and Woll,
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationHistotype or molecular driven treatment of sarcomas?
Histotype or molecular driven treatment of sarcomas? Prof.ssa Maria A Pantaleo Dipartimento Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna GistStudyGroup Sarcomastudygroup Bologna
More informationSummary... 2 SARCOMA Neoadjuvant chemotherapy in patients with localised high-risk STS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 SARCOMA... 3 Neoadjuvant chemotherapy in patients with localised high-risk STS... 3 No additional benefit with evofosfamide
More informationTherapeutic Algorithms in systemic sarcoma therapy
Therapeutic Algorithms in systemic sarcoma therapy Ian Judson Sarcoma Unit Royal Marsden Hospital What evidence do we have? What sorts of evidence are there? Experience personal, peers ( Bayesian ) Educational
More informationNew and Emerging Therapies for Soft Tissue Sarcomas and GIST: Recent Clinical Data and Expert Recommendations
New and Emerging Therapies for Soft Tissue Sarcomas and GIST: Recent Clinical Data and Expert Recommendations George D. Demetri, M.D. Director, Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationPerspectives in 2 nd line treatment of advanced Soft tissue Sarcoma treatment approaches. Dr.Dana Stănculeanu Bucharest Institute of Oncology
Perspectives in 2 nd line treatment of advanced Soft tissue Sarcoma treatment approaches Dr.Dana Stănculeanu Bucharest Institute of Oncology Epidemiology of soft tissue sarcoma STS accounts for
More informationUpdate on Sarcomas of the Head and Neck. Kevin Harrington
Update on Sarcomas of the Head and Neck Kevin Harrington Overview Classification and incidence of sarcomas Clinical presentation Challenges to treatment Management approaches Prognostic factors Radiation-induced
More informationThe evidence for and against neoadjuvant chemotherapy in localized STS
The evidence for and against neoadjuvant chemotherapy in localized STS Axel Le Cesne Gustave Roussy, Villejuif French Sarcoma Group EORTC, CTOS Académie de Médecine Drugs Practice, 2 nd of December 2016
More informationScientific Perspectives of Olaratumab Beyond the Approval Indication
Scientific Perspectives of Olaratumab Beyond the Approval Indication William D. Tap, MD Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center GEIS XVI International Symposium October
More informationClinical Study A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas
Sarcoma Volume 2006, Article ID 5947, Pages 4 DOI 0.55/SRCM/2006/5947 Clinical Study A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas Sibyl
More informationA stratified clinical approach to uterine sarcoma
A stratified clinical approach to uterine sarcoma Martee L. Hensley, MD Memorial Sloan-Kettering Cancer Center Gynecologic Medical Oncology Weill Cornell Medical College New York, NY USA Disclosure slide
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationNew Biological and Immunological Therapies for Cancer
New Biological and Immunological Therapies for Cancer Sant P. Chawla, M.D., FRACP The Sarcoma Oncology Center, Santa Monica CA 90403 7 th International Conference on Drug Discovery &Therapy 1 Promising
More informationAdult-type soft tissue sarcomas are a variegate group of
Adjuvant Chemotherapy for Soft Tissue Sarcoma Paolo G. Casali, MD OVERVIEW Adjuvant chemotherapy is not standard treatment in soft tissue sarcoma (STS). However, when the risk of relapse is high, it is
More informationA PHASE 1B DOSE-ESCALATION STUDY OF TRC105 (ANTI-ENDOGLIN ANTIBODY) IN COMBINATION WITH PAZOPANIB IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS)
A PHASE 1B DOSE-ESCALATION STUDY OF TRC105 (ANTI-ENDOGLIN ANTIBODY) IN COMBINATION WITH PAZOPANIB IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) S. Attia 1, R.F. Riedel 2, S.I. Robinson 3, R.M. Conry
More informationWhat is New in Front-line Treatment of Advanced / Metastatic Soft Tissue Sarcomas?
What is New in Front-line Treatment of Advanced / Metastatic Soft Tissue Sarcomas? 14 th of December 2017, International Expert Time Grandangolo in Oncologia 2017, Genua, Italy Bernd Kasper University
More informationSarcomas. Living Beyond Cancer A-Z UT Health San Antonio MD Anderson Cancer Center
Sarcomas Living Beyond Cancer A-Z UT Health San Antonio MD Anderson Cancer Center Aaron Sugalski, DO Associate Professor of Pediatric Hematology/Oncology Medical Director, UHS Pediatric Blood and Cancer
More informationDr. Myo Myint Maw Senior Consultant Physician Medical Oncology Unit Yangon General Hospital
Dr. Myo Myint Maw Senior Consultant Physician Medical Oncology Unit Yangon General Hospital *Sarcoma constitutes 2% of cancer patients attended at medical oncology unit of Yangon General Hospital.(2014-2015)
More informationNew chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD
New chemotherapy drugs in metastatic breast cancer Guy Jerusalem, MD, PhD MBC Patients survival over time Median survival increases over time, but is still measured in months This is not yet a chronic
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Pazopanib (Votrient) for Soft Tissue Sarcoma November 29, 2012
pan-canadian Oncology Drug Review Final Clinical Guidance Report Pazopanib (Votrient) for Soft Tissue Sarcoma November 29, 2012 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationIncorporating the patient voice in sarcoma research:
Incorporating the patient voice in sarcoma research: How can we assess health-related quality of life in this heterogeneous patient groep? Olga Husson PhD Institute of Cancer Research, Division of Clinical
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationInternational Collaborations on Sarcomas. Alessandro Gronchi
International Collaborations on Sarcomas Alessandro Gronchi alessandro.gronchi@istitutotumori.mi.it EORTC STBSG World Sarcoma Network Investigators initiated Trials (national groups, centers, etc.) 33
More informationCom cal fer la primera maniobre terapèutica en els sarcomes d extremitats. Tractament sistèmic.
Com cal fer la primera maniobre terapèutica en els sarcomes d extremitats. Tractament sistèmic. Dr. Javier Martín Broto Oncología Médica. HU Son Espases. Palma www.cotmes.com DIAGNOSTIC PROCEDURE: CRUCIAL
More informationKeep Calm and Love France. Robin L Jones Royal Marsden Hospital Institute of Cancer Research
Keep Calm and Love France Robin L Jones Royal Marsden Hospital Institute of Cancer Research Plan Parallels between France - UK - USA Importance of centralized care Improving Outcome Guidance (IOG) in UK/
More informationCommon disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,
Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000
More informationSoft Tissue Sarcoma. Presley Regional Trauma Center Department of Surgery University of Tennessee Health Science Center Memphis, Tennessee
Soft Tissue Sarcoma Presley Regional Trauma Center Department of Surgery University of Tennessee Health Science Center Memphis, Tennessee Soft Tissue Sarcoma Collective term for an unusual and diverse
More informationManagement of Retroperitoneal Sarcomas
Management of Retroperitoneal Sarcomas Giorgos C. Karakousis, M.D. Division of Endocrine and Oncologic Surgery Department of Surgery University of Pennsylvania School of Medicine Sarcomas General Background
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationMultidisciplinary management of retroperitoneal sarcomas
Multidisciplinary management of retroperitoneal sarcomas Eric K. Nakakura, MD UCSF Department of Surgery UCSF Comprehensive Cancer Center San Francisco, CA 7 th Annual Clinical Cancer Update North Lake
More informationOverview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationGemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
pissn 1598-2998, eissn 25-9256 Cancer Res Treat. 218;5(1):175-182 Original Article https://doi.org/1.4143/crt.216.535 Open Access Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma:
More informationNeodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
More informationResearch Article Epidemiology, Treatment Patterns, and Outcomes of Metastatic Soft Tissue Sarcoma in a Community-Based Oncology Network
Hindawi Publishing Corporation Sarcoma Volume 2014, Article ID 145764, 7 pages http://dx.doi.org/10.1155/2014/145764 Research Article Epidemiology, Treatment Patterns, and Outcomes of Metastatic Soft Tissue
More informationKEY ADVANCES IN THE SYSTEMIC THERAPY FOR SOFT TISSUE SARCOMAS: CURRENT STATUS AND FUTURE DIRECTIONS
KEY ADVANCES IN THE SYSTEMIC THERAPY FOR SOFT TISSUE SARCOMAS: CURRENT STATUS AND FUTURE DIRECTIONS Neelesh Soman, 1 James Hu, 2 Vivek Subbiah, 3 and Sant Chawla 1 1. Sarcoma Oncology Center, Santa Monica,
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationReview Article A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma
Sarcoma Volume 2016, Article ID 3597609, 13 pages http://dx.doi.org/10.1155/2016/3597609 Review Article A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationContents Part I Introduction 1 General Description 2 Natural History: Importance of Size, Site, Histopathology
Contents Part I Introduction 1 General Description... 3 1.1 Introduction... 3 1.2 Incidence and Prevalence... 5 1.3 Predisposing and Genetic Factors... 8 References... 16 2 Natural History: Importance
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationPancreatic Ca Update
Pancreatic Ca Update Caio Max S. Rocha Lima, M.D. M. Robert Cooper Professor in Medical Oncology Co-leader GI Oncology and Co-leader Phase I Program Wake Forest School of Medicine E-mail:crochali@wakehealth.edu
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationCombining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer
Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer Dr Martin Forster MD PhD Clinical Senior Lecturer in Experimental Cancer Medicine Consultant in Medical Oncology UCL
More informationRecent Advances in Gastrointestinal Cancers
Recent Advances in Gastrointestinal Cancers Ursina R. Teitelbaum, MD Section of Hematology/Oncology Abramson Cancer Center PENN 2016 Updates in Oncology June 23, 2016 none Disclosures ASCO 2016 Highlights:
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationWhat s New in Radiotherapy For STS of The Extremity? Kaled M. Alektiar, MD, FASTRO Dept of Rad Onc Memorial Sloan Kettering Cancer Center
What s New in Radiotherapy For STS of The Extremity? Kaled M. Alektiar, MD, FASTRO Dept of Rad Onc Memorial Sloan Kettering Cancer Center Topics Predictive tools for risk assessment Reassessment of dose/volume
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationTough to treat tumors in elderly. how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France
Tough to treat tumors in elderly Pancreatic cancer: how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France Top 5 causes of cancer death / age Cancer Statistics in the USA 2008, CA
More informationDrug Comparison: Lartruvo TM (Olaratumab) for Soft Tissue Sarcoma By: Majd Abedrabbo, PharmD Candidate 2018 Fairleigh Dickinson University School of
Drug Comparison: Lartruvo TM (Olaratumab) for Soft Tissue Sarcoma By: Majd Abedrabbo, PharmD Candidate 2018 Fairleigh Dickinson University School of Pharmacy May 3, 2017 Introduction Soft Tissue Sarcoma
More informationDesigning New Clinical Trials for Desmoid Tumors
Designing New Clinical Trials for Desmoid Tumors Sant P. Chawla, MD Director, Sarcoma Oncology Center Santa Monica CA 90403 2017 DTRF Desmoid Tumor Research Workshop September 24, 2017, Philadelphia, 2017
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationPancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
More informationLatest Advances in Targeted Therapy and Immunotherapy in Sarcomas. Robin L Jones Royal Marsden Hospital Institute of Cancer Research
Latest Advances in Targeted Therapy and Immunotherapy in Sarcomas Robin L Jones Royal Marsden Hospital Institute of Cancer Research Disclosures Consultant for: Adaptimmune Blueprint Clinigen Eisai Epizyme
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationToxicities of Chemotherapy Regimens used in Early Breast Cancer
Toxicities of Chemotherapy Regimens used in Early Breast Cancer CERCIT Workshop February 17, 2012 Carlos H Barcenas, M.D., M.S. Fellow Hematology-Oncology MD Anderson Cancer Center CERCIT Scholar Outline
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationtrabectedin, 0.25 and 1mg powder for concentrate for solution for infusion (Yondelis ) SMC No. (452/08) Pharma Mar S.A. Sociedad Unipersonal
trabectedin, 0.25 and 1mg powder for concentrate for solution for infusion (Yondelis ) SMC No. (452/08) Pharma Mar S.A. Sociedad Unipersonal 08 October 2010 The Scottish Medicines Consortium (SMC) has
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationOpinion 24 July 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 YONDELIS 0.25 mg, powder for concentrate for solution for infusion Box of 1 vial (CIP: 571 522-9) YONDELIS
More informationBest of ASCO 2014 Sarcoma
Best of ASCO 2014 Sarcoma Robin L Jones Seattle Cancer Care Alliance University of Washington Fred Hutchinson Cancer Research Center Presentation Outline Overview progress made in sarcoma Highlight 2 trials
More informationSoft Tissue Sarcoma: What is best practice?
Soft Tissue Sarcoma: What is best practice? 18:30-19:45, Thursday 10th November 2016 Opala Rooms I, II and III, 1st Floor, Corinthia Hotel Lisbon Chaired by Alessandro Gronchi With Angelo Paolo Dei Tos,
More informationMusculoskeletal Sarcomas
Musculoskeletal Sarcomas Robert C. Orth, M.D., Ph.D. Edward B. Singleton Department of Pediatric Radiology Texas Children s Hospital Page 0 xxx00.#####.ppt 9/23/2012 9:01:18 AM No disclosures Page 1 xxx00.#####.ppt
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationSPAEN Meeting: Desmoid Tumors
SPAEN Meeting: Desmoid Tumors 23 rd of November 2012, Firenze, Italy Update on systemic treatment options and clinical trials in desmoids Bernd Kasper University of Heidelberg Mannheim University Medical
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationIMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA
IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More information